Product Information
BUFFERED ASPIRIN 325 MG TB is a generic product labeled by Cardinal Health, priced at $0.0207 per EA under NDC 70000014701. Its NADAC has been published 406 times since Dec 26, 2018.
Strength
325 mg/1
Manufacturer
Cardinal HealthNDC
70000014701
Classification
Generic
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
6/17/2026
Active Ingredients
ASPIRINApproval Type
OTC MONOGRAPH DRUG
FDA Application
M013On Market Since
3/30/1990
Pharmacological Classes
Price Statistics
The NADAC for BUFFERED ASPIRIN 325 MG TB has been published 406 times since Dec 26, 2018, and over the history we have for it it has risen 11.8%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.0207 per EA |
|---|---|
| All-time high | $0.0220 (Aug 14, 2024) |
| All-time low | $0.0176 (Apr 22, 2020) |
| 52-week high | $0.0207 |
| 52-week low | $0.0198 |
| Median price | $0.0192 |
| Average price | $0.0194 |
| Largest weekly change | +17.7% (Jan 19, 2022) |
| Weeks tracked | 406 |
| Tracking since | Dec 26, 2018 |
Generic Alternatives
The matcher finds 7 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 42% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Cardinal Health manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Aspirin market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Nonsteroidal Anti-inflammatory Drug class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of BUFFERED ASPIRIN 325 MG TB?
The current National Average Drug Acquisition Cost (NADAC) for BUFFERED ASPIRIN 325 MG TB, manufactured by Cardinal Health, is $0.0207 per EA (NDC 70000014701), effective Sep 30, 2026.
How has the price of BUFFERED ASPIRIN 325 MG TB changed over time?
Over the history we have for it, the NADAC for BUFFERED ASPIRIN 325 MG TB has risen 11.8%. It has been tracked across 406 weekly CMS publications since Dec 26, 2018.
What are the highest and lowest recorded NADAC prices for BUFFERED ASPIRIN 325 MG TB?
Since Dec 26, 2018, the NADAC for BUFFERED ASPIRIN 325 MG TB has ranged from a low of $0.0176 (Apr 22, 2020) to a high of $0.0220 (Aug 14, 2024), with a median of $0.0192 per EA.
Are there cheaper alternatives to BUFFERED ASPIRIN 325 MG TB?
Yes. 7 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, QC ASPIRIN 325 MG TABLET, is $0.0121 per EA — about 42% below BUFFERED ASPIRIN 325 MG TB.
Who manufactures BUFFERED ASPIRIN 325 MG TB?
BUFFERED ASPIRIN 325 MG TB (NDC 70000014701) is labeled by Cardinal Health, and CMS classifies it as a generic product.